Ilorasertib (ABT-348)

ilorasertib · Abbott/AbbVie (joint development context not specified in snippet)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ilorasertib (ABT-348), covering 2023-07-17 to 2023-07-17. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors [Phase 2]